Bosch Healthcare Solutions (BHCS) has announced the launch of the Vivalytic Bordetella test, a groundbreaking advancement in near-patient diagnostics that significantly enhances the detection of whooping cough. This innovative PCR test uniquely identifies all three major whooping cough pathogens: Bordetella pertussis, Bordetella parapertussis, and Bordetella holmesii. This new addition to the Vivalytic analysis platform aims to address the rising incidence of pertussis and provide timely, accurate diagnoses at local healthcare facilities.
Innovative PCR Testing for Whooping Cough
The Vivalytic Bordetella test represents a significant leap forward in diagnostic technology, enabling the rapid detection of the pathogens responsible for whooping cough within one hour. Unlike traditional methods, which often require up to a week for results, this test delivers results quickly, facilitating prompt and effective treatment. The test is currently offered for vehicles featuring BMW Operating Systems 8, 8.5, and 9, and will soon be accessible for those equipped with Operating System 7.
Marc Meier, President of Bosch Healthcare Solutions, highlights the importance of this advancement: “Vivalytic Bordetella is our response to the rising number of pertussis cases in Germany. Pertussis poses a significant risk, particularly to infants, the elderly, and individuals with pre-existing health conditions, necessitating rapid diagnosis.”
The Urgency of Rapid Diagnosis
Pertussis typically begins with mild symptoms such as a cough, sneezing, and a runny nose, which can quickly escalate to a severe, characteristic cough. The disease is particularly dangerous for infants and the elderly, with over 90% of affected infants under three months old requiring hospitalization. Dr. Stefan Zimmermann of Heidelberg University Hospital emphasizes the critical role of early diagnosis: “Prompt treatment is crucial for Bordetella infections, as the course and severity of the cough can only be mitigated if antibiotic therapy begins early.”
The Vivalytic Bordetella test addresses the need for rapid near-patient testing, which is essential for effective treatment and controlling the spread of the disease. With two-thirds of pertussis cases occurring in adolescents and adults, the ability to quickly identify and treat infections is vital for preventing further transmission.
Addressing Rising Pertussis Cases
Germany has experienced a significant increase in pertussis cases in 2024, with over 11,000 cases reported by the end of July. The surge is attributed to diminished immunity from COVID-19 protection measures and a decrease in vaccination rates. This trend underscores the need for efficient diagnostic tools like the Vivalytic Bordetella test, which can help mitigate the impact of whooping cough by providing rapid results and facilitating prompt treatment.
Comprehensive Detection of Pertussis Pathogens
The Vivalytic Bordetella test not only identifies B. pertussis, but also B. parapertussis and B. holmesii. Recent data shows an increase in B. parapertussis infections, which now account for a significant portion of cases. The test’s ability to differentiate between these pathogens is crucial for accurate diagnosis and effective treatment, as each pathogen varies in virulence and impact on patients.
User-Friendly Testing and Automation
The Vivalytic Analyser streamlines rapid testing within medical practices, boasting a user-friendly design that demands minimal training for healthcare professionals. The test cartridge, which contains all necessary reagents, is inserted into the Vivalytic Analyser for automatic processing. This fully automated process, combined with a deactivating sample medium, reduces the risk of infection and ensures precise, timely results. Bosch Healthcare Solutions has recently obtained CE certification for the Vivalytic Bordetella test, further validating its effectiveness and reliability.
The Vivalytic Bordetella test marks a significant advancement in near-patient diagnostics, providing healthcare providers with a powerful tool to combat the rising incidence of whooping cough and improve patient outcomes.
